Skip to content

FALCON Trial Testing Measures to Reduce Surgical Site Infection

Pragmatic Multicentre FActorial Randomised Controlled triaL Testing Measures to reduCe Surgical Site Infection in lOw and Middle Income couNtries

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03700749
Acronym
FALCON
Enrollment
5480
Registered
2018-10-09
Start date
2018-11-29
Completion date
2021-07-31
Last updated
2019-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Surgery, Surgical Site Infection

Brief summary

FALCON is a Pragmatic multi-centre trial testing measures to reduce superficial or deep skin infection following abdominal surgery in low and middle income countries. The trial will recruit patients undergoing abdominal surgery. Recruited participants will be randomly assigned to four arms to receive different combinations of skin preparation and sutures for would closure: A. In this arm surgeon will use 2% alcoholic chlorhexidine for skin cleansing and non-coated suture for wound closure; B. In this arm surgeon will use 2% alcoholic chlorhexidine for skin cleansing and triclosan coated suture for wound closure; C. In this arm surgeon will use for operation 10% aqueous povidone-iodine for skin cleansing and non-coated suture for wound closure; D. In this arm surgeon will use 10% aqueous povidone-iodine for skin cleansing and triclosan-coated suture.

Detailed description

FALCON is a pragmatic, blinded (patient and outcome assessor), 2x2 factorial, stratified, multi-centre randomised controlled trial, with an internal pilot, to evaluate measures to reduce Surgical Site Infection (SSI) rates in patients undergoing surgery with an abdominal incision. Surgical site infection (SSI) represents a major burden for patients, doctors, and health systems across all settings. SSI is the commonest postoperative complication worldwide and the commonest healthcare-associated infection in low and middle income countries (LMICs). SSIs cause pain, discomfort, disability, and increase the time taken to return to work (3). SSIs increase healthcare costs in all health settings. Whilst there is no direct data on the costs of SSI in LMICs, within the UK National Health Service, SSIs cost approximately £3500 per patient and £700 million per year in total. The impact of increased healthcare costs on patients, communities, and providers can be major in LMICs where personal income is low and patients may be required to pay for their own treatment. SSI has also been associated with one-third of postoperative deaths and accounts for 8% of all deaths caused by a hospital acquired infection. Strata in FALCON trial are defined according to the anticipated category of wound contamination: (1) clean-contaminated and (2) contaminated/dirty. Eligible patients will be randomised at the level of the individual in a 1:1:1:1 ratio between: A. 2% alcoholic chlorhexidine and non-coated suture B. 2% alcoholic chlorhexidine and triclosan-coated suture C. 10% aqueous povidone-iodine and non-coated suture D. 10% aqueous povidone-iodine and triclosan-coated suture. Participant will be recruited from hospitals in Low and Middle Income Countries (LMICs). Participants who is undergoing abdominal surgery with an anticipated clean-contaminated, contaminated or dirty surgical wound will be selected to enter the trial. The 6 month internal pilot will assess the feasibility of recruitment, compliance with treatment allocation and patient retention and follow-up rates. The main RCT will recruit 5480 participants.

Interventions

DRUG2% chlorhexidine + non-coated suture

Interventions: 2% alcoholic chlorhexidine non-coated suture

DRUG2% chlorhexidine + coated suture

Interventions: 2% alcoholic chlorhexidine triclosan coated suture

DRUG10%povidone-iodine + non-coated suture

Interventions: 10% povidone-iodine non-coated suture non-coated suture

DRUG10%povidone-iodine + coated suture

Interventions: 10% povidone-iodine triclosan coated suture

Sponsors

Lagos State University
CollaboratorOTHER
Universidad Francisco Marroquín
CollaboratorOTHER
Kigali University Teaching Hospital
CollaboratorOTHER
Christian Medical College and Hospital, Ludhiana, India
CollaboratorOTHER
University of Edinburgh
CollaboratorOTHER
University of the Philippines
CollaboratorOTHER
King Edward Medical University
CollaboratorOTHER
University of Witwatersrand, South Africa
CollaboratorOTHER
Universidad Peruana Cayetano Heredia
CollaboratorOTHER
Centre National Hospitalier Universitaire
CollaboratorUNKNOWN
Ndola Teaching Hospital
CollaboratorUNKNOWN
Hospital Espanol de Veracruz
CollaboratorUNKNOWN
Ministry of Health, Ghana
CollaboratorOTHER_GOV
University of Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Patients and outcome assessors will be blinded. The operating surgeon will not perform outcome assessment.

Intervention model description

FALCON 2x2 factorial trial with strata: (1) clean-contaminated and (2) contaminated/dirty. Eligible patients will be randomised at the level of the individual in a 1:1:1:1 ratio between: A. 2% alcoholic chlorhexidine and non-coated suture B. 2% alcoholic chlorhexidine and triclosan-coated suture C. 10% aqueous povidone-iodine and non-coated suture D. 10% aqueous povidone-iodine and triclosan-coated suture

Eligibility

Sex/Gender
ALL
Age
No minimum to 100 Years
Healthy volunteers
No

Inclusion criteria

* Patients with at least one abdominal incision that is ≥5cm (open or laparoscopic extraction site), with an anticipated clean-contaminated, contaminated or dirty surgical wound. * Patients undergoing emergency (surgery on an unplanned admission) or elective (surgery on a planned admission) operations. * Any operative indication, including trauma surgery. * Patient able and willing to provide written informed consent (signature or a fingerprint). * Paediatric and adult patients. This criteria is made country-specific. Each country decides the lower age limit for the trial. This is dependent on country-specific regulatory approvals. Age eligibility will vary by country.

Exclusion criteria

* Patients with a documented or suspected allergy to iodine, shellfish, or chlorhexidine skin preparation solution. * Patient unable to complete post-operative follow-up (i.e. will not be contactable after discharge).

Design outcomes

Primary

MeasureTime frameDescription
Surgical site infection (SSI)At 30-days post-surgeryDeep incisional or superficial incisional SSI which must occur within 30 days of the index operation. The infection must involve the skin, subcutaneous, muscular or fascial layers of the incision. Patient must at least have one of the following: (1) purulent discharge from wound; (2) organisms detected from wound swab; (3) Wound opened spontaneously or by a clinician AND, at the surgical wound, the patient has at least one of: pain or tenderness; localised swelling; redness; heat; systemic fever (\>38°C); (4) Diagnosis of SSI by a clinician or on imaging.

Secondary

MeasureTime frameDescription
Mortality - patient mortality statusWithin 30-days post surgery from index operationMortality within 30-days post surgery
Physiological parameter - Unplanned wound openingWithin 30-days post surgery from index operationWhether an unplanned wound opening has occurred at abdominal surgical site within 30-days post surgery, spontaneously opened or by clinician
Re-operation for SSIWithin 30-days post surgery from index operationRe-operation for SSI within 30-days post surgery
Length of hospital stay for index admissionWithin 30-days post surgery from index operationLength of hospital stay for index admission will be collected and will measure time from surgery to time of discharge.
Physiological parameter - SSI at discharge from hospitalWithin 30-days post surgery from index operationDeep incisional or superficial incisional SSI. The infection must involve the skin, subcutaneous, muscular or fascial layers of the incision and the patient must have one of the following: (1) purulent discharge from wound; (2) organisms detected from wound swab; (3) Wound opened spontaneously or by a clinician AND, at the surgical wound, the patient has at least one of: pain or tenderness; localised swelling; redness; heat; systemic fever (\>38°C); (4) Diagnosis of SSI by a clinician or on imaging.
Questionnaire - return to normal activitiesWithin 30-days post surgery from index operationReturn to normal activities (e.g. work, school, or family duties) ascertained by trial specific questionnaire
Resistance of organismsWithin 30-days post surgery from index operationResistance of organisms detected from wound swabs to prophylactic antibiotics administered within 1 hour of incision
Questionnaire - Health resource usageWithin 30-days post surgery. Health resource usage will only be collected for adult patients (aged 18 and above) at pre-selected centres. This will include costs of post-operative visits to various healthcare professionals.Health resource usage within 30-days post surgery ascertained by trial specific questionnaire
Participant's ReadmissionWithin 30-days post surgery from index operationWhether patient readmitted within 30-days post surgery

Countries

Nigeria

Contacts

Primary ContactTina Griffin, BMedSc
falcon@trials.bham.ac.uk0121 414 4762
Backup ContactRachel Lillywhite, BA
GlobalSurg@trials.bham.ac.uk0121 414 4762

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026